Last10K.com

Cardiol Therapeutics Inc. (CRDL) SEC Filing 6-K Foreign Issuer Report for the period ending Tuesday, February 8, 2022

Cardiol Therapeutics Inc.

HISTORY TOOLS
CIK: 1702123 Ticker: CRDL

View differences made from one to another to evaluate Cardiol Therapeutics Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 6-K Foreign Issuer Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Cardiol Therapeutics Inc..

Continue

Assess how Cardiol Therapeutics Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Cardiol Therapeutics Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Material Contracts, Statements, Certifications & more

Cardiol Therapeutics Inc. provided additional information to their SEC Filing as exhibits

Exhibit 99.1: Additional Exhibits
Exhibit 99.2: Additional Exhibits
Ticker: CRDL
CIK: 1702123
Form Type: 6-K Foreign Issuer Report
Accession Number: 0001104659-22-013943
Submitted to the SEC: Tue Feb 08 2022 5:17:42 PM EST
Accepted by the SEC: Tue Feb 08 2022
Period: Tuesday, February 8, 2022
Industry: Biological Products No Disgnostic Substances

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/crdl/0001104659-22-013943.htm